ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy.
Journal Information
Full Title: Cancer Cell Int
Abbreviation: Cancer Cell Int
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Ethics approval and consent to participateAnimal studies were conducted after the approval of a local ethical committee. Consent for publicationAll the authors consent to publication. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"Funding This work was supported by the University of Mons, the Health Institute of the University of Mons, the FRMH, “Les amis de l’Institut Bordet” from the Jules Bordet Institute (Brussels, Belgium) and the Botalys company for the in vivo part."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025